Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
Sponsor: Denali Therapeutics Inc.
Summary
This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) period. Part A will evaluate the safety, tolerability, PK, and PD of single doses of DNL593 in healthy male and healthy female participants of nonchildbearing potential. Part B will evaluate the safety, tolerability, PK, and PD of multiple doses of DNL593 in participants with frontotemporal dementia (FTD) over 25 weeks. Part B will be followed by Part C, an optional 18-month OLE period available for all participants who complete Part B.
Official title: A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label Extension
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
85
Start Date
2022-02-01
Completion Date
2028-11
Last Updated
2026-01-15
Healthy Volunteers
Yes
Conditions
Interventions
DNL593
Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
Placebo
Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
Locations (26)
University of California San Francisco
San Francisco, California, United States
John Hopkins University
Baltimore, Maryland, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Antwerp
Antwerp, Belgium
UZ Leuven
Leuven, Belgium
L2IP - Instituto de Pesquisas Clinicas LTDA
Brasília, Brazil
Faculdade de Medicina Da Universidade de São Paulo
São Paulo, Brazil
Hospital Universitario San Ignacio
Bogotá, Colombia
Grupo de Neurosicencias de la Universidad de Antioquia
Medellín, Colombia
Fakultni nemocnice v Motole
Prague, Czechia
CHU de Nantes
Nantes, France
CHU Rouen
Rouen, France
CHU Toulouse
Toulouse, France
ASST degli Spedali Civili di Brescia
Brescia, Italy
Azienda Ospedaliera Universitaria Careggi
Florence, Italy
IRCCS Istituto Auxologico Italiano
Milan, Italy
Azienda Ospedaliera Cardinale G Panico
Tricase, Italy
Erasmus University Medical Center
Rotterdam, Netherlands
Hospital de Braga
Braga, Portugal
Campus Neurológico Sénior
Torres Vedras, Portugal
Hospital Clinic de Barcelona
Barcelona, Barcelona, Spain
Hospital Universitario de Donostia
Donostia / San Sebastian, Guipúzcoa, Spain
Hospital Universitario Virgen del Rocio
Seville, Sevilla, Spain
Istanbul University Istanbul Medical Faculty
Istanbul, Turkey (Türkiye)
Ondokuz Mayis University Hospital
Samsun, Turkey (Türkiye)
Simbec Orion
Merthyr Tydfil, Wales, United Kingdom